S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

CYTO Altamira Therapeutics Ltd

0.30

0.00 (0.00%)

Jan 30 2025 - Closed

Delayed by 15 minutes

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]

null

Altamira Therapeutics (NASDAQ:CYTO)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Altamira Therapeutics Charts.

Altamira Therapeutics (NASDAQ:CYTO)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Altamira Therapeutics Charts.

Altamira Therapeutics Ltd News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Friday 20 December 2024 (1 month ago) • Edgar (US Regulatory)

Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets
Friday 20 December 2024 (1 month ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Friday 4 October 2024 (4 months ago) • Edgar (US Regulatory)

Altamira Therapeutics Provides Update on Nasdaq Listing
Friday 4 October 2024 (4 months ago) • GlobeNewswire Inc.

Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
Friday 27 September 2024 (4 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Tuesday 24 September 2024 (4 months ago) • Edgar (US Regulatory)

Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
Tuesday 24 September 2024 (4 months ago) • GlobeNewswire Inc.

Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
Friday 20 September 2024 (4 months ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 19 September 2024 (4 months ago) • Edgar (US Regulatory)

Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
Thursday 19 September 2024 (4 months ago) • GlobeNewswire Inc.

Form 424B4 - Prospectus [Rule 424(b)(4)]
Wednesday 18 September 2024 (4 months ago) • Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness
Tuesday 17 September 2024 (5 months ago) • Edgar (US Regulatory)

More Altamira Therapeutics Ltd News Articles

Northwest Biotherapeutics (QB)

Bioelectronics (PK)

Lightwave Logic

North Bay Resources (PK)

Fannie Mae (QB)

Elite Pharmaceuticals (QB)

Anavex Life Sciences

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions